


Supplementary Table 1. Baseline characteristics of patients in the meta-analysis

Author, year	Mean age (years)	Male (%)	Disease duration (years)	Previous TNF antagonist use (%)	Immuno-modulator use at baseline (%)	Corticosteroid use at baseline (%)	Disease site (I/C/IC, %)	Mean CDAI
Feagan B.G., 2017	37.5	39.0	13	88	26	31	31/55/81	297.5 (Median)
Sands B.E., 2017	36.5	37.8	12.2	100	27	40	27/29/44	318.6
D'Haens G., 2022	37.5	54.0	8.8	96	24	30	15/36/50	313.0
D'Haens G., 2022	39.6	51.0	11.7	95	23	34	14/39/47	314.2
Sands B.E., 2022	38.8	48.6	9.6	59	32	30	17/39/43	313.9
Sandborn W.J., 2022	38.8	59.2	8.8	53	36	37	29/42/29	309.0
Sandborn W.J., 2012	39.0	41.3	12.3	99	24	50	–	323.9
Feagan B.G., 2016	37.3	42.7	12.2	0	31	46	14/17/69	322.5
Feagan B.G., 2016	39.2	46.7	9.3	68	29	39	23/20/57	302.8
Sandborn W.J., 2022	38.8	59.2	8.8	53	36	37	29/42/29	309

TNF – tumor necrosis factor, I – ileum, C – colon, IC – ileum and colon, CDAI – Crohn's Disease Activity Index

**Fig. S1.** Quality assessment of each study included in this meta-analysis

Study	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
D'Haens, Geert 2022	+	+	+	+	+	?	?
Feagan, B. G. 2016	+	+	+	+	+	?	?
Feagan, Brian G. 2017	+	+	+	+	+	+	+
Sandborn, W. J. 2012	+	+	+	+	+	+	+
Sandborn, W. J. 2022	+	+	+	+	-	+	?
Sands, B. E. 2017	+	+	+	+	-	+	?
Sands, B. E. 2022	+	+	+	+	+	?	?
Sands, Bruce E. 2022	+	+	+	+	+	?	-

Fig. S2. Quality assessment of studies included in this meta-analysis (Risk of bias summary)